Fair value $0.30 vs current $1.37 implies 78% downside risk. Monopolistic MRI-compatible cardiac ablation technology with FDA approval catalyst, but extreme 195x revenue valuation creates unfavourable risk-reward profile.
View noteMining technology leader trading at 44% premium to $2.36 fair value. Strong 29.3% EBITDA margins, 490+ patents, but execution risks from three simultaneous acquisitions amid uncertain exploration recovery.
View noteAustralia's #2 diagnostic imaging provider trading at 129% premium to $1.16 fair value. High leverage, workforce constraints, and technology disruption create asymmetric downside risk.
View noteClinical-stage biotechnology company trading at $1.62 vs fair value $0.13, facing 65% Phase 2 failure probability with extreme dilution risk ahead.
View noteHarvey Norman trades at $7.29 vs $3.13 fair value (57% overvalued) with unsustainable margins and property cycle risks creating compelling value opportunity
View noteTrading at $1.00 vs fair value $0.88. Business quality 5.9/10, EBITDA margins compressing 49.9% to 44.7%. Development pipeline finite, competitive moat narrowing 4-6 years.
View noteHOLD rating with $2.26 fair value vs $2.65 current price. Strong 5.85% dividend yield offset by customer concentration risks and margin compression pressures.
View noteHOLD rating with $4.75 fair value vs $5.27 current price. 98.5% occupancy but office headwinds and 7.2x leverage create challenging outlook.
View noteHOLD rating with $3.61 fair value vs $4.27 current price. Exceptional ROIC 71.6% offset by cyclical peak timing concerns and inevitable margin compression.
View noteTrading at $35.89 vs fair value $18.38 (95% premium). Development margins at 47.8% face compression to 42%. ROIC 8.2% trails WACC 9.6%. Quality business, extreme valuation.
View noteGenesis Minerals trades at A$4.53 versus fair value A$1.75 (-61%), with 49.4% EBITDA margins facing compression to 39% as grade depletes from 2.7g/t to 2.0g/t. ROIC 21.8%, narrow moat (6-8 years), high execution risk on A$1.5bn expansion.
View noteHOLD rating with fair value $0.133 vs current $0.150. Market leader in ANZ adventure tourism with 25% share, EBITDA margins at 14.7%, facing climate and competitive headwinds.
View note